GHRP-6 vs Tesamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
GHRP-6
Growth Hormone Releasing Peptide 6 (GHRP-6) is one of the first synthetic growth hormone secretagogues discovered. It stimulates significant GH release but is known for causing intense hunger.
Full details →Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Side-by-Side Comparison
| Aspect | GHRP-6 | Tesamorelin |
|---|---|---|
| Dose Range | 100 mcg–300 mcg | 2 mg |
| Frequency | 3x daily | 1x daily |
| Cycle Length | 8–12 weeks | 8–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Acts as a ghrelin mimetic, binding to the GHS-R receptor in the pituitary and hypothalamus. Stimulates GH release and also significantly increases appetite by mimicking ghrelin's hunger-signaling effects. | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily. Often combined with GHRH peptides like CJC-1295 for synergistic effects. | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. |
| Administration | Subcutaneous injection. Best administered on an empty stomach. The strong hunger response can be beneficial for those trying to gain weight but challenging for cutting. | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. |
| Side Effects | Intense hunger (most notable effect), water retention, increased cortisol and prolactin, tingling/numbness, and potential blood pressure changes. | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. |
| Best For |
What They Have in Common
GHRP-6, Tesamorelin are both commonly used for:
Key Differences
Unique to GHRP-6:
Unique to Tesamorelin:
Which Has Stronger Evidence?
- Muscle Growth: GHRP-6 has stronger research support.
| Goal | GHRP-6 | Tesamorelin |
|---|---|---|
| Muscle Growth | high | medium |
Key Studies
GHRP-6
- Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.
Journal of nanobiotechnology, 2025
- Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.
Frontiers in pharmacology, 2024
- [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle.
Molecular and cellular endocrinology, 2015
Tesamorelin
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
BMJ open, 2026
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
The Journal of infectious diseases, 2025
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
AIDS (London, England), 2024
Ready to Learn More?
Looking for trusted sources?